EUVIMEDEUVIMED entdecken
Übersichtsarbeit

MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations

Ferdinando D'Amico, Francesca Lusetti, Laurent Peyrin-Biroulet, Silvio Danese

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2024.04.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Ferdinando D'Amico und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Mesalamine, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medical therapy is the cornerstone of ulcerative colitis (UC) management and aims to induce and maintain remission. In case of mild-to-moderate UC, mesalamine (5-ASA) is the first-line option. 5-ASA requires local release at the level of the inflamed mucosa to exert its therapeutic action. While rectal preparations are useful in distal colitis, in cases of UC of at least rectosigmoid extent, guidelines suggest the association of oral and rectal 5-ASA. Mesalamine with Multi Matrix System® technology (MMX mesalamine) is an oral, high-strength (1.2 g/tablet), once-daily formulation of 5-ASA, designed to provide delayed and prolonged release throughout the entire colon. Clinical trials demonstrated a strong efficacy in inducing and maintaining clinical and endoscopic remission in active mild-to-moderate UC. The efficacy is related to specific colonic drug-delivery, to its high-dosage and once-daily administration, thus improving patients' adherence and outcomes. The specific colonic-delivery is also associated with very low rates of systemic absorption and adverse events (AEs). With this comprehensive review we aimed to summarize current knowledge on MMX mesalamine in mild-to-moderate UC, in terms of clinical pharmacology, efficacy and safety, also compared to other 5-ASA products. In addition we provided an expert opinion on the topic, examining the implications on clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeMesalamineAnti-Inflammatory Agents, Non-SteroidalHumansDelayed-Action PreparationsAdministration, OralAdministration, Rectal

Stichwörter der Autor:innen

5-ASAInflammatory bowel diseaseMMX mesalamineUlcerative colitis

Substanzen

MesalamineAnti-Inflammatory Agents, Non-SteroidalDelayed-Action Preparations

Autor:innen und Institutionen

  • Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
  • Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy; Gastroenterology Unit, Foundation Policlinico San Matteo IRCCS, University of Pavia, Pavia, Italy.
  • Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France, Inserm, NGERE, University of Lorraine, F-54000 Nancy, France; INFINY Institute, Nancy University Hospital, F-54500 Vandœuvr…
  • Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy. Electronic address: sdanese@hotmail.com.

Zitieren

APA

D'Amico, F., Lusetti, F., Peyrin-Biroulet, L., & Danese, S. (2024). MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.04.012

Vancouver

D'Amico F, Lusetti F, Peyrin-Biroulet L, Danese S. MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.04.012

BibTeX
@article{DAmico2024,
  author = {D'Amico, Ferdinando and Lusetti, Francesca and Peyrin-Biroulet, Laurent and Danese, Silvio},
  title = {MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2024.04.012}
}
Kostenlos starten →